Bone Metastases
169
21
31
74
Key Insights
Highlights
Success Rate
83% trial completion
Published Results
26 trials with published results (15%)
Research Maturity
74 completed trials (44% of total)
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 52/100
8.9%
15 terminated out of 169 trials
83.1%
-3.4% vs benchmark
13%
22 trials in Phase 3/4
35%
26 of 74 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.5%
Based on 74 completed trials
Clinical Trials (169)
Post-Op Pain Control for Prophylactic Intramedullary Nailing.
Registry for Bone Metastases
Prophylactic Radiotherapy to Prevent Bone Complications in Patients With Metastatic Solid Cancers
Denosumab Strategy for Liver Cancer With Bone Metastases
Denosumab in Combination With Enzalutamide in Progressive Metastatic Castrate-resistant Prostate Cancer and Bone Metastases.
EXercise Enhancement After RadioTherapy for Bone Metastases
Prostate Cancer With OligometaSTatic Relapse: Combining Stereotactic Ablative Radiotherapy and Durvalumab (MEDI4736)
Prospective Evaluation of Interventional Studies on Bone Metastases - the PRESENT Cohort
Focused Ultrasound and RadioTHERapy for Noninvasive Palliative Pain Treatment in Patients With Bone Metastases
SBRT Technique Implementation for Spinal Metastases Irradiation
A Phase III Study of Radium-223 Dichloride in Patients With Symptomatic Hormone Refractory Prostate Cancer With Skeletal Metastases
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
Radiosurgical Hypophysectomy for Bone Metasteses Pain
Early Radiotherapy Versus Observation for High-risk Asymptomatic or Minimally Symptomatic Bone Metastases
A Phase III Randomized Trial Comparing Stereotactic Body Radiation Therapy (SBRT) vs Conventional Palliative Radiation Therapy for Painful Bone Metastases
Improving a Bayesian Model's Survival Estimates in Patients Needing Surgery for Bone Metastases
Prevention of Symptomatic Skeletal Events With Denosumab Administered Every 4 Weeks Versus Every 12 Weeks
BOne Metastases REgistry for Patients Undergoing cryoAbLation With curatIve purpoSe
Fracture Risk Evaluation of Bone Metastases Derived From Carcinoma
Standard Treatment +/- SBRT in Solid Tumors Patients With Between 1 and 5 Bone-only Metastases